New drug shows promise for dialysis patients with hormone imbalance

NCT ID NCT05836220

Completed Disease control Sponsor: Pathalys Pharma Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times

Summary

This study tested a new medicine called PLS240 in 412 adults with end-stage kidney disease on dialysis who also have overactive parathyroid glands (secondary hyperparathyroidism). The goal was to see if PLS240 can safely lower high parathyroid hormone levels better than a placebo. Participants received either the drug or a placebo for 27 weeks, then everyone could receive the drug for another 26 weeks. The study is now complete.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Site Number: BGR001-2

Gabrovo, 5300, Bulgaria
Site Number: BGR002-2

Rousse, 7002, Bulgaria
Site Number: BGR003-2

Lom, Montana, 3600, Bulgaria
Site Number: BGR004-2

Varna, 9000, Bulgaria
Site Number: ESP003-2

Córdoba, Cordoba, 14004, Spain
Site Number: ESP005-2

Manises, Valencia, 46940, Spain
Site Number: POL001-2

Lodz, Lódzkie, 90-242, Poland
Site Number: POL002-2

Poznan, Greater Poland Voivodeship, 60-214, Poland
Site Number: POL004-2

Tomaszów Mazowiecki, Lódzkie, 97-200, Poland
Site Number: POL005-2

Warsaw, Masovian Voivodeship, 02-758, Poland
Site Number: PRT001-2

Carnaxide, 2790-134, Portugal
Site Number: PRT002-2

Covilha, Castelo Branco District, 6200-000, Portugal
Site Number: PRT003-2

Lisbon, 1250-203, Portugal
Site Number: SRB001-2

Kruševac, 37000, Serbia
Site Number: SRB002-2

Niš, 18000, Serbia
Site Number: SRB003-2

Belgrade, 11000, Serbia
Site Number: SRB004-2

Užice, 31000, Serbia
Site Number: SRB005-2

Belgrade, Belgrade, 11080, Serbia
Site Number: USA001-2

Chula Vista, California, 91910-3813, United States
Site Number: USA002-2

Hollywood, Florida, 33024-2776, United States
Site Number: USA003-2

San Diego, California, 92111-3636, United States
Site Number: USA004-2

Fort Myers, Florida, 33908-4154, United States
Site Number: USA005-2

La Mesa, California, 91942-3017, United States
Site Number: USA006-2

Waxahachie, Texas, 75165-1399, United States
Site Number: USA007-2

Amherst, New York, 14228-2792, United States
Site Number: USA008-2

San Antonio, Texas, 78251-4125, United States
Site Number: USA009-2

Toledo, Ohio, 43606-1171, United States
Site Number: USA010-2

Greenville, South Carolina, 29605-4019, United States
Site Number: USA011-2

El Paso, Texas, 79925-4828, United States
Site Number: USA012-2

San Antonio, Texas, 78221-3019, United States
Site Number: USA013-2

Columbus, Georgia, 31904-3603, United States
Site Number: USA015-2

Newark, Delaware, 19713-2081, United States
Site Number: USA016-2

Minneapolis, Minnesota, 55404-1212, United States
Site Number: USA017-2

Middlebury, Connecticut, 06762-2843, United States
Site Number: USA018-2

San Dimas, California, 91773-3539, United States
Site Number: USA019-2

Granada Hills, California, 91344-7407, United States
Site Number: USA020-2

Escondido, California, 92025-4402, United States
Site Number: USA021-2

Tarzana, California, 91356-3647, United States
Site Number: USA022-2

Moorpark, California, 93021-3352, United States
Site Number: USA023-2

Arvada, Colorado, 80002-3714, United States
Site Number: USA024-2

Wichita, Kansas, 67214-2944, United States
Site Number: USA025-2

Kalamazoo, Michigan, 49007-3889, United States
Site Number: USA026-2

Durham, North Carolina, 27704-2147, United States
Site Number: USA027-2

Knoxville, Tennessee, 37923-3624, United States
Site Number: USA028-2

Mishawaka, Indiana, 46545-3519, United States
Site Number: USA029-2

Live Oak, Texas, 78233-4767, United States
Site Number: USA030-2

Los Angeles, California, 90022-4302, United States
Site Number: USA031-2

Aurora, Colorado, 80045-7202, United States
Site Number: USA033-2

Northridge, California, 91324-3528, United States
Site Number: USA034-2

Fullerton, California, 92832-3037, United States
Site Number: USA035-2

South Miami, Florida, 33143-5522, United States
Site Number: USA037-2

Norfolk, Virginia, 23507-1901, United States
Site Number: USA038-2

St. George, Utah, 84790-5898, United States
Site Number: USA039-2

Anaheim, California, 92801-6731, United States
Site Number: USA041-2

Orlando, Florida, 32801, United States
Site Number: USA042-2

Fresno, California, 93720-3389, United States
Site Number: USA043-2

Los Angeles, California, 90033, United States
Site Number: USA044-2

Lancaster, California, 93534-2831, United States
Site Number: USA045-2

Roseburg, Oregon, 97471-6214, United States
Site Number: USA046-2

Glendale, California, 91205-3313, United States
Site Number: USA048-2

Detroit, Michigan, 48236-2169, United States
Site Number: USA049-2

Northridge, California, 91324-2927, United States
Site Number: USA051-2

Fairfax, Virginia, 22033-1907, United States
Site Number: USA052-2

Victorville, California, 92395-8322, United States
Site Number: USA053-2

Charlotte, North Carolina, 28208-3876, United States
Site Number: USA054-2

New Orleans, Louisiana, 70112, United States
Site Number: USA055-2

Prosper, Texas, 75078-1411, United States
Site Number: USA056-2

Tarzana, California, 91356-2806, United States

Conditions

Explore the condition pages connected to this study.

END-STAGE KIDNEY DISEASE END-STAGE KIDNEY DISEASE SECONDARY HYPERPARATHYROIDISM SECONDARY HYPERPARATHYROIDISM